Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.49 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.39 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18063589 | 1.00 | PDE4B (0.49) | PDE4BCRBNIKZF3ALDH1A1HTR2A | |
| SCHEMBL19035903 | 0.91 | CRBN (0.47) | PDE4BCRBNIKZF3ALDH1A1GRIN1 | |
| SCHEMBL38659705 | 0.90 | CRBN (0.48) | PDE4BCRBNIKZF3ALDH1A1HTR2A | |
| SCHEMBL18929514 | 0.90 | PDE4B (0.46) | PDE4BCRBNIKZF3ALDH1A1HTR2A | |
| SCHEMBL31151947 | 0.89 | CRBN (0.46) | PDE4BCRBNIKZF3ALDH1A1HTR2A | |
| SCHEMBL18087015 | 0.87 | ALDH1A1 (0.48) | PDE4BCRBNALDH1A1HTR2AHTR2C | |
| SCHEMBL17918579 | 0.87 | ALDH1A1 (0.48) | PDE4BCRBNALDH1A1HTR2AHTR2C | |
| SCHEMBL15821845 | 0.85 | CRBN (0.48) | PDE4BCRBNIKZF3ALDH1A1HTR2A | |
| SCHEMBL18929351 | 0.85 | CRBN (0.48) | PDE4BCRBNIKZF3ALDH1A1HTR2A | |
| SCHEMBL31151999 | 0.85 | CRBN (0.48) | PDE4BCRBNIKZF3ALDH1A1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3245213-B1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL MYERS SQUIBB CO (US) | 2020-03-04 | — | — | EP | disclosed |
| US-20180079781-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-22 | — | — | US | disclosed |
| US-20180037581-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL MYERS SQUIBB CO (US) | 2018-02-08 | — | — | US | disclosed |
| US-9822112-B2 | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-9822144-B2 | Benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170233436-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-17 | — | — | US | disclosed |
| US-20170233392-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-17 | — | — | US | disclosed |
| US-9676775-B2 | Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676794-B2 | Benzodiazepine dimers, conjugates thereof, and methods of making and using | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233392-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA2, GABRA3 | PDE4B 4745/4885CRBN 350/4885IKZF3 1809/4885 |
| US-20180037581-A1 | HETEROARYLENE-BRIDGED BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA2, GABRA3 | PDE4B 4745/4885CRBN 350/4885IKZF3 1809/4885 |
| US-20170233436-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA3, GABRA2 | PDE4B 4327/4885CRBN 286/4885IKZF3 1768/4885 |
| US-20180079781-A1 | BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, AND METHODS OF MAKING AND USING | GABRA1, GABRA3, GABRA2 | PDE4B 4327/4885CRBN 286/4885IKZF3 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.